Relationship between depth of response and outcome in multiple myeloma

David M Dingli, Jorge M. Pacheco, Grzegorz S Nowakowski, Shaji K Kumar, Angela Dispenzieri, Suzanne R. Hayman, Martha Lacy, Dennis A. Gastineau, Morie Gertz

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Purpose: High-dose therapy with autologous stem-cell transplantation (HDT-ASCT) is now almost standard therapy for many patients with multiple myeloma, partly because of higher complete response (CR) rates. Some studies suggest that tandem transplantation gives superior results. The aim of this study was to determine whether the depth of the response to HDT-ASCT leads to an improvement in time to progression (TTP) and overall survival (OS). We hypothesized that patients with CR before HDT-ASCT (BCR) will have their disease burden reduced further and experience a longer TTP and perhaps OS. Patients and Methods: All patients who achieved BCR or CR after HDT-ASCT (ACR) were identified. The characteristics and long-term outcome of these patients were evaluated. Results: We identified 14 patients with BCR and 103 patients with ACR who were treated in similar fashion. The patients have been followed for more than 6 years, and the median for OS has not been reached (60-month survival, 55% for BCR and 63% for ACR; P = .83). The median TTP was 43 months for BCR and 34 months for ACR (P = .39). Conclusion: The depth of the response in myeloma does not necessarily lead to an improvement in TTP and OS. Tumor dynamics considerations show that the yield from sequential cycles of chemotherapy decreases. Patients who achieve CR with the first transplant can be safely observed without jeopardizing OS.

Original languageEnglish (US)
Pages (from-to)4933-4937
Number of pages5
JournalJournal of Clinical Oncology
Volume25
Issue number31
DOIs
StatePublished - Nov 1 2007
Externally publishedYes

Fingerprint

Multiple Myeloma
Stem Cell Transplantation
Survival
Therapeutics
Transplantation
Transplants
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Relationship between depth of response and outcome in multiple myeloma. / Dingli, David M; Pacheco, Jorge M.; Nowakowski, Grzegorz S; Kumar, Shaji K; Dispenzieri, Angela; Hayman, Suzanne R.; Lacy, Martha; Gastineau, Dennis A.; Gertz, Morie.

In: Journal of Clinical Oncology, Vol. 25, No. 31, 01.11.2007, p. 4933-4937.

Research output: Contribution to journalArticle

@article{c479d72efdeb467cb2b6f967d22e74b2,
title = "Relationship between depth of response and outcome in multiple myeloma",
abstract = "Purpose: High-dose therapy with autologous stem-cell transplantation (HDT-ASCT) is now almost standard therapy for many patients with multiple myeloma, partly because of higher complete response (CR) rates. Some studies suggest that tandem transplantation gives superior results. The aim of this study was to determine whether the depth of the response to HDT-ASCT leads to an improvement in time to progression (TTP) and overall survival (OS). We hypothesized that patients with CR before HDT-ASCT (BCR) will have their disease burden reduced further and experience a longer TTP and perhaps OS. Patients and Methods: All patients who achieved BCR or CR after HDT-ASCT (ACR) were identified. The characteristics and long-term outcome of these patients were evaluated. Results: We identified 14 patients with BCR and 103 patients with ACR who were treated in similar fashion. The patients have been followed for more than 6 years, and the median for OS has not been reached (60-month survival, 55{\%} for BCR and 63{\%} for ACR; P = .83). The median TTP was 43 months for BCR and 34 months for ACR (P = .39). Conclusion: The depth of the response in myeloma does not necessarily lead to an improvement in TTP and OS. Tumor dynamics considerations show that the yield from sequential cycles of chemotherapy decreases. Patients who achieve CR with the first transplant can be safely observed without jeopardizing OS.",
author = "Dingli, {David M} and Pacheco, {Jorge M.} and Nowakowski, {Grzegorz S} and Kumar, {Shaji K} and Angela Dispenzieri and Hayman, {Suzanne R.} and Martha Lacy and Gastineau, {Dennis A.} and Morie Gertz",
year = "2007",
month = "11",
day = "1",
doi = "10.1200/JCO.2007.11.7879",
language = "English (US)",
volume = "25",
pages = "4933--4937",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "31",

}

TY - JOUR

T1 - Relationship between depth of response and outcome in multiple myeloma

AU - Dingli, David M

AU - Pacheco, Jorge M.

AU - Nowakowski, Grzegorz S

AU - Kumar, Shaji K

AU - Dispenzieri, Angela

AU - Hayman, Suzanne R.

AU - Lacy, Martha

AU - Gastineau, Dennis A.

AU - Gertz, Morie

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Purpose: High-dose therapy with autologous stem-cell transplantation (HDT-ASCT) is now almost standard therapy for many patients with multiple myeloma, partly because of higher complete response (CR) rates. Some studies suggest that tandem transplantation gives superior results. The aim of this study was to determine whether the depth of the response to HDT-ASCT leads to an improvement in time to progression (TTP) and overall survival (OS). We hypothesized that patients with CR before HDT-ASCT (BCR) will have their disease burden reduced further and experience a longer TTP and perhaps OS. Patients and Methods: All patients who achieved BCR or CR after HDT-ASCT (ACR) were identified. The characteristics and long-term outcome of these patients were evaluated. Results: We identified 14 patients with BCR and 103 patients with ACR who were treated in similar fashion. The patients have been followed for more than 6 years, and the median for OS has not been reached (60-month survival, 55% for BCR and 63% for ACR; P = .83). The median TTP was 43 months for BCR and 34 months for ACR (P = .39). Conclusion: The depth of the response in myeloma does not necessarily lead to an improvement in TTP and OS. Tumor dynamics considerations show that the yield from sequential cycles of chemotherapy decreases. Patients who achieve CR with the first transplant can be safely observed without jeopardizing OS.

AB - Purpose: High-dose therapy with autologous stem-cell transplantation (HDT-ASCT) is now almost standard therapy for many patients with multiple myeloma, partly because of higher complete response (CR) rates. Some studies suggest that tandem transplantation gives superior results. The aim of this study was to determine whether the depth of the response to HDT-ASCT leads to an improvement in time to progression (TTP) and overall survival (OS). We hypothesized that patients with CR before HDT-ASCT (BCR) will have their disease burden reduced further and experience a longer TTP and perhaps OS. Patients and Methods: All patients who achieved BCR or CR after HDT-ASCT (ACR) were identified. The characteristics and long-term outcome of these patients were evaluated. Results: We identified 14 patients with BCR and 103 patients with ACR who were treated in similar fashion. The patients have been followed for more than 6 years, and the median for OS has not been reached (60-month survival, 55% for BCR and 63% for ACR; P = .83). The median TTP was 43 months for BCR and 34 months for ACR (P = .39). Conclusion: The depth of the response in myeloma does not necessarily lead to an improvement in TTP and OS. Tumor dynamics considerations show that the yield from sequential cycles of chemotherapy decreases. Patients who achieve CR with the first transplant can be safely observed without jeopardizing OS.

UR - http://www.scopus.com/inward/record.url?scp=36849031848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36849031848&partnerID=8YFLogxK

U2 - 10.1200/JCO.2007.11.7879

DO - 10.1200/JCO.2007.11.7879

M3 - Article

VL - 25

SP - 4933

EP - 4937

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 31

ER -